



New Technologies for Tuberculosis Control:



RETOOLING
TASK FORCE

A framework for their adoption,
introduction and implementation





RETOOLING
TASK FORCE

New Technologies for Tuberculosis Control:

A framework for their adoption,
introduction and implementation

WHO Library Cataloguing-in-Publication Data

New technologies for Tuberculosis control : a framework for their adoption, introduction and implementation.

“WHO/HTM/STB/2007.40”.

1.Tuberculosis - prevention and control. 2.Diffusion of innovation. 3.Health policy. I.World Health Organization. II.Stop TB Partnership. Task Force on Retooling.

ISBN 978 92 4 159552 0

(NLM classification: WF 200)

© World Health Organization 2007

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [HYPERLINK “mailto:bookorders@who.int”](mailto:bookorders@who.int) bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in France

Contents

Acknowledgements	I
Abbreviations	III
Preface	VI
Foreword	VII
Executive summary	IX
1. Introduction	1
1.1 Background information on challenges to global TB control	1
1.2 The Global Plan to Stop TB	1
1.3 The Stop TB Partnership Task Force on Retooling	2
2. New technologies to control the spread of TB	3
2.1 Objectives, contents and assumptions of the framework	3
2.2 Objectives of new technologies for TB control	4
2.3 Expected timeline for new technologies	6
2.4 Challenges to timely and appropriate adoption, introduction and implementation	7
2.5 Actions that facilitate timely and appropriate adoption, introduction and implementation	8
3. Adoption and development of new policies at global and country levels	11
3.1 Essential components	11
4. Introduction and implementation of new technologies	21
4.1 Technical considerations	22
4.2 Operational considerations	28
4.3 Monitoring and evaluation	38
5. The way forward	41
6. References	43
Annex 1: What is in the TB pipeline (November 2006)?	46
Annex 2: Key actions for new anti-TB regimens (illustrative)	72
Annex 3: Key actions for new TB diagnostics (illustrative)	80
Annex 4: Key actions for new anti-TB vaccines (illustrative)	88
Annex 5: Timeline for adoption and implementation (illustrative)	96
Annex 6: Further reading	98

Acknowledgements

The following individuals were involved in the development of this framework, and their contribution is gratefully acknowledged.

Stop TB Partnership Task Force on Retooling

Mohamed Aziz, Rachel Bauquerez (Secretariat), Léopold Blanc, Saidi Egwaga, Sarah England (Secretariat), Carole Francis, Ulrich Joseph Fruth, Christy Hanson, Barbara Laughon, Robert Matiru, Lindiwe Mvusi, Vinand Nantulya (Co-chair), Ikushi Onozaki, Philip Onyebujoh, Andrew Ramsay, Nina Schwalbe (Co-chair), Birte Holm Sorensen, Javid Syed, Karin Weyer.

Stop TB Partnership working groups

Advocacy, Communication and Social Mobilization Working Group

Paul John Sommerfeld (Chair), Carole Francis (Secretariat).

Subgroup on Advocacy, Communication and Social Mobilization at Country Level

Dr Roberto Tapia-Conyer (Chair), Nicole Schiegg (Secretariat).

DOTS Expansion Working Group

Jeremiah Chakaya (Chair), Léopold Blanc (Secretariat).

Working Group on MDR-TB

Thelma E. Tupasi-Ramos (Chair), Dr Ernesto Jaramillo (Secretariat).

TB/HIV Working Group

Diane Havlir (Chair), Haileyesus Getahun (Secretariat).

Working Group on New TB Diagnostics

Giorgio Roscigno (Chair), Andrew Ramsay (Secretariat).

Working Group on New TB Drugs

Maria C. Freire (Chair), Barbara Laughon (Secretariat).

Working Group on New TB Vaccines

Michel Greco (Chair), Ulrich Fruth (Secretariat).

Management Sciences for Health/Rational Pharmaceutical Management Plus Program

Niranjan Konduri, David Lee, Evan Lee, Helena Walkowiak.

The following staff from Management Sciences for Health reviewed and commented on versions of the draft: Grace Adeya, Edgar Barillas, Andrew Barraclough, Malcolm Clark, Tom Moore, Catherine Mundy, Jim Rankin, Pedro Suarez, Hugo Vrakking, Andrey Zagorskiy.

Other reviewers and contributors were Chris Dye, Marcos Espinal, Tom Kanyok, Orin Levine, Rosanna Peeling, Thadeus Pennas, Mario Raviglione, Jerry Sadoff, Kate Thomson, Armand van Deun, Veronique Vincent and Patrick Zuber.

The development of this framework was made possible through the generous contribution of the following funding sources:

- Global Alliance for TB Drug Development
- Foundation for Innovative New Diagnostics
- UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases
- United States Agency for International Development, through its Rational Pharmaceutical Management Plus Program (Cooperative Agreement HRN-A-00-00-00016-00)
- Stop TB Partnership

Abbreviations

ACSM	advocacy, communication and social mobilization
AEFI	adverse events following immunization
Aeras	Aeras Global TB Vaccine Foundation
AIDS	acquired immunodeficiency syndrome
BCG	Bacille Calmette-Guérin (vaccine)
CDC	United States Centers for Disease Control and Prevention
DFID	United Kingdom Department for International Development
DHS	demographic and health surveys
DOTS	The internationally recommended strategy for TB control until 2005, and the foundation of WHO's new Stop TB Strategy in 2006
DST	drug susceptibility testing
EML	essential medicines list
EPI	expanded programme on immunization
FDC	fixed-dose combination
FIND	Foundation for Innovative New Diagnostics
GAVI	Global Alliance for Vaccines and Immunization
GDF	Global Drug Facility
Global Fund	Global Fund to Fight AIDS, Tuberculosis and Malaria
GLC	Green Light Committee
GMP	good manufacturing practice
GTZ	Deutsche Gesellschaft für Technische Zusammenarbeit [German Development Agency]
HIV	human immunodeficiency virus
HMIS	health management information system
MDR-TB	multidrug-resistant tuberculosis
NGO	nongovernmental organization
NTD	national tuberculosis control programme

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29610

